Results 111 to 120 of about 4,926,176 (337)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

New Oncologic Drugs from 2008 to 2023—Differences in Approval and Access between the United States, Europe and Brazil

Current Oncology
Introduction: Advancements in oncology have revolutionized cancer treatment, with new drugs being approved at different rates worldwide. Our objective was to evaluate the approval of new oncological drugs for solid tumors by the Food and Drug ...
Rafael Balsini Barreto, Andressa Moretti Izidoro, Mario Henrique Furlanetto Miranda   +2 more
doaj   +1 more source

Challenges of globalization of cancer drug trials- recruitment in LMICs, approval in HICs

, 2021
Bishal Gyawali, Laura M. Carson, Scott Berry, Fábio Ynoe de Moraes   +3 more
openalex   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Drug approvals in India [PDF]

The Lancet Diabetes & Endocrinology, 2016
Mukul, Jain, Rajendrakumar H, Jani
openaire   +4 more sources

Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016 [PDF]

, 2020
Joanna P. MacEwan, Syvart Dennen, Rebecca Kee, Farzad Ali, Jason Shafrin, Katharine Batt   +5 more
openalex   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

DRUG LAG FOR ANTIMICROBIAL AGENTS: COMPARISON OF THE US, EU AND INDIA APPROVALS

National Journal of Medical Research, 2012
Background: Antimicrobial resistance is a global problem and the need for new antimicrobial agents is greater in both developed and developing nations.
Bhaven C Kataria, Dimple S Mehta , Sanjay J Mehta   +2 more
doaj  

Current philosophical perspectives on drug approval in the real world

Journal of Causal Inference
The evidence-based medicine approach to causal medical inference is the dominant account among medical methodologists. Competing approaches originating in the philosophy of medicine seek to challenge this account.
Landes Jürgen, Auker-Howlett Daniel J.
doaj   +1 more source

Food and Drug Administration Approval of Use of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine [PDF]

, 1992
Elaine Larson
openalex   +1 more source